Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran

BACKGROUND/AIMS: Dabigatran, an oral direct thrombin inhibitor, is used in patients with non-valvular atrial fibrillation to reduce thromboembolic events. Whereas the 150 mg dosing regimen has been extensively studied in clinical setting, to date, there is no clinical data on the 75 mg (low dose, “L...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi, Ramin, Han, Janet K., Goe, Seung H., Treadwell, Michelle, Feliciano, Zenaida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502329/
https://www.ncbi.nlm.nih.gov/pubmed/28740848
http://dx.doi.org/10.3389/fcvm.2017.00042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502329/
https://www.ncbi.nlm.nih.gov/pubmed/28740848
http://dx.doi.org/10.3389/fcvm.2017.00042

Ejemplares similares